Predictive Model of Type 2 Diabetes Remission after Metabolic Surgery in Chinese Patients
Introduction. Metabolic surgery is an effective treatment for type 2 diabetes (T2D). At present, there is no authoritative standard for predicting postoperative T2D remission in clinical use. In general, East Asian patients with T2D have a lower body mass index and worse islet function than westerne...
Gespeichert in:
Veröffentlicht in: | International journal of endocrinology 2020, Vol.2020 (2020), p.1-13 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 13 |
---|---|
container_issue | 2020 |
container_start_page | 1 |
container_title | International journal of endocrinology |
container_volume | 2020 |
creator | Zhao, Shaoli Yang, Youbo He, Honghui Guo, Zi Luo, Yufang Mo, Zhaohui |
description | Introduction. Metabolic surgery is an effective treatment for type 2 diabetes (T2D). At present, there is no authoritative standard for predicting postoperative T2D remission in clinical use. In general, East Asian patients with T2D have a lower body mass index and worse islet function than westerners. We aimed to look for clinical predictors of T2D remission after metabolic surgery in Chinese patients, which may provide insights for patient selection. Methods. Patients with T2D who underwent metabolic surgery at the Third Xiangya Hospital between October 2008 and March 2017 were enrolled. T2D remission was defined as an HbA1c level below 6.5% and an FPG concentration below 7.1 mmol/L for at least one year in the absence of antidiabetic medications. Results. (1) Independent predictors of short-term T2D remission (1-2 years) were age and C-peptide area under the curve (C-peptide AUC); independent predictors of long-term T2D remission (4–6 years) were C-peptide AUC and fasting plasma glucose (FPG). (2) The optimal cutoff value for C-peptide AUC in predicting T2D remission was 30.93 ng/ml, with a specificity of 67.3% and sensitivity of 75.8% in the short term and with a specificity of 61.9% and sensitivity of 81.5% in the long term, respectively. The areas under the ROC curves are 0.674 and 0.623 in the short term and long term, respectively. (3) We used three variables (age, C-peptide AUC, and FPG) to construct a remission prediction score (ACF), a multidimensional 9-point scale, along which greater scores indicate a better chance of T2D remission. We compared our scoring system with other reported models (ABCD, DiaRem, and IMS). The ACF scoring system had the best distribution of patients and prognostic significance according to the ROC curves. Conclusion. Presurgery age, C-peptide AUC, and FPG are independent predictors of T2D remission after metabolic surgery. Among these, C-peptide AUC plays a decisive role in both short- and long-term remission prediction, and the optimal cutoff value for C-peptide AUC in predicting T2D remission was 30.93 ng/ml, with moderate predictive values. The ACF score is a simple reliable system that can predict T2D remission among Chinese patients. |
doi_str_mv | 10.1155/2020/2965175 |
format | Article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_pubmed_primary_33488705</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A697015824</galeid><doaj_id>oai_doaj_org_article_a546b8c96cc44ee0a2b493defa4ee0e7</doaj_id><sourcerecordid>A697015824</sourcerecordid><originalsourceid>FETCH-LOGICAL-c635t-bb94559b1b8bc4d23e1d7dd17b225a076fe9db22a79f782a76526839b324a55e3</originalsourceid><addsrcrecordid>eNqNkstvEzEQxlcIREvhxhlZQkJIkNZvey9IVXhVakUF5cDJ8tqziaPtOrV3i_Lf45CQNogD8sGv33xjz3xV9ZzgY0KEOKGY4hNaS0GUeFAdEqnVRDMuHu7WTB1UT3JeYCylxORxdcAY11phcVj9uEzggxvCLaCL6KFDsUVXqyUgit4H28AAGX2F65BziD2y7QAJXcBgm9gFh76NaQZphUKPpvPQQwZ0aYcA_ZCfVo9a22V4tp2Pqu8fP1xNP0_Ov3w6m56eT5xkYpg0Tc2FqBvS6MZxTxkQr7wnqqFUWKxkC7Uva6vqVukySUGlZnXDKLdCADuqzja6PtqFWaZwbdPKRBvM74OYZsamIbgOjBVcNtrV0jnOAbClDa-Zh9aud6CK1ruN1nJsrsG78o9kuz3R_Zs-zM0s3hqltNKCF4HXW4EUb0bIgymVc9B1toc4ZkO5xkpQzNa5Xv6FLuKY-lKqQgnNiyQVd9TMlg-Evo0lr1uLmlNZK0yEpuu0x_-gyvClcy720IZyvhfw6l7AHGw3zHPsxqE0Oe-DbzegSzHnBO2uGASbtf_M2n9m67-Cv7hfwB38x3AFeLMBilu8_Rn-Uw4KU9p0R5PywJqyXx8y6aA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2458477825</pqid></control><display><type>article</type><title>Predictive Model of Type 2 Diabetes Remission after Metabolic Surgery in Chinese Patients</title><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Zhao, Shaoli ; Yang, Youbo ; He, Honghui ; Guo, Zi ; Luo, Yufang ; Mo, Zhaohui</creator><contributor>Kin, Tatsuya ; Tatsuya Kin</contributor><creatorcontrib>Zhao, Shaoli ; Yang, Youbo ; He, Honghui ; Guo, Zi ; Luo, Yufang ; Mo, Zhaohui ; Kin, Tatsuya ; Tatsuya Kin</creatorcontrib><description>Introduction. Metabolic surgery is an effective treatment for type 2 diabetes (T2D). At present, there is no authoritative standard for predicting postoperative T2D remission in clinical use. In general, East Asian patients with T2D have a lower body mass index and worse islet function than westerners. We aimed to look for clinical predictors of T2D remission after metabolic surgery in Chinese patients, which may provide insights for patient selection. Methods. Patients with T2D who underwent metabolic surgery at the Third Xiangya Hospital between October 2008 and March 2017 were enrolled. T2D remission was defined as an HbA1c level below 6.5% and an FPG concentration below 7.1 mmol/L for at least one year in the absence of antidiabetic medications. Results. (1) Independent predictors of short-term T2D remission (1-2 years) were age and C-peptide area under the curve (C-peptide AUC); independent predictors of long-term T2D remission (4–6 years) were C-peptide AUC and fasting plasma glucose (FPG). (2) The optimal cutoff value for C-peptide AUC in predicting T2D remission was 30.93 ng/ml, with a specificity of 67.3% and sensitivity of 75.8% in the short term and with a specificity of 61.9% and sensitivity of 81.5% in the long term, respectively. The areas under the ROC curves are 0.674 and 0.623 in the short term and long term, respectively. (3) We used three variables (age, C-peptide AUC, and FPG) to construct a remission prediction score (ACF), a multidimensional 9-point scale, along which greater scores indicate a better chance of T2D remission. We compared our scoring system with other reported models (ABCD, DiaRem, and IMS). The ACF scoring system had the best distribution of patients and prognostic significance according to the ROC curves. Conclusion. Presurgery age, C-peptide AUC, and FPG are independent predictors of T2D remission after metabolic surgery. Among these, C-peptide AUC plays a decisive role in both short- and long-term remission prediction, and the optimal cutoff value for C-peptide AUC in predicting T2D remission was 30.93 ng/ml, with moderate predictive values. The ACF score is a simple reliable system that can predict T2D remission among Chinese patients.</description><identifier>ISSN: 1687-8337</identifier><identifier>EISSN: 1687-8345</identifier><identifier>DOI: 10.1155/2020/2965175</identifier><identifier>PMID: 33488705</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Age ; Analysis ; Antidiabetics ; Body mass index ; Care and treatment ; Diabetes ; Diabetes therapy ; Drugs ; Endocrinology ; Gastrointestinal surgery ; Glycosylated hemoglobin ; Homeostasis ; Hypertension ; Hypoglycemic agents ; Insulin resistance ; Medical research ; Medicine, Experimental ; Metabolism ; Obesity ; Peptides ; Regression analysis ; Remission (Medicine) ; Type 2 diabetes</subject><ispartof>International journal of endocrinology, 2020, Vol.2020 (2020), p.1-13</ispartof><rights>Copyright © 2020 Yufang Luo et al.</rights><rights>COPYRIGHT 2020 John Wiley & Sons, Inc.</rights><rights>Copyright © 2020 Yufang Luo et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2020 Yufang Luo et al. 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c635t-bb94559b1b8bc4d23e1d7dd17b225a076fe9db22a79f782a76526839b324a55e3</citedby><cites>FETCH-LOGICAL-c635t-bb94559b1b8bc4d23e1d7dd17b225a076fe9db22a79f782a76526839b324a55e3</cites><orcidid>0000-0002-2295-0213 ; 0000-0002-5181-048X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787854/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787854/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,873,881,2096,4010,27900,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33488705$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Kin, Tatsuya</contributor><contributor>Tatsuya Kin</contributor><creatorcontrib>Zhao, Shaoli</creatorcontrib><creatorcontrib>Yang, Youbo</creatorcontrib><creatorcontrib>He, Honghui</creatorcontrib><creatorcontrib>Guo, Zi</creatorcontrib><creatorcontrib>Luo, Yufang</creatorcontrib><creatorcontrib>Mo, Zhaohui</creatorcontrib><title>Predictive Model of Type 2 Diabetes Remission after Metabolic Surgery in Chinese Patients</title><title>International journal of endocrinology</title><addtitle>Int J Endocrinol</addtitle><description>Introduction. Metabolic surgery is an effective treatment for type 2 diabetes (T2D). At present, there is no authoritative standard for predicting postoperative T2D remission in clinical use. In general, East Asian patients with T2D have a lower body mass index and worse islet function than westerners. We aimed to look for clinical predictors of T2D remission after metabolic surgery in Chinese patients, which may provide insights for patient selection. Methods. Patients with T2D who underwent metabolic surgery at the Third Xiangya Hospital between October 2008 and March 2017 were enrolled. T2D remission was defined as an HbA1c level below 6.5% and an FPG concentration below 7.1 mmol/L for at least one year in the absence of antidiabetic medications. Results. (1) Independent predictors of short-term T2D remission (1-2 years) were age and C-peptide area under the curve (C-peptide AUC); independent predictors of long-term T2D remission (4–6 years) were C-peptide AUC and fasting plasma glucose (FPG). (2) The optimal cutoff value for C-peptide AUC in predicting T2D remission was 30.93 ng/ml, with a specificity of 67.3% and sensitivity of 75.8% in the short term and with a specificity of 61.9% and sensitivity of 81.5% in the long term, respectively. The areas under the ROC curves are 0.674 and 0.623 in the short term and long term, respectively. (3) We used three variables (age, C-peptide AUC, and FPG) to construct a remission prediction score (ACF), a multidimensional 9-point scale, along which greater scores indicate a better chance of T2D remission. We compared our scoring system with other reported models (ABCD, DiaRem, and IMS). The ACF scoring system had the best distribution of patients and prognostic significance according to the ROC curves. Conclusion. Presurgery age, C-peptide AUC, and FPG are independent predictors of T2D remission after metabolic surgery. Among these, C-peptide AUC plays a decisive role in both short- and long-term remission prediction, and the optimal cutoff value for C-peptide AUC in predicting T2D remission was 30.93 ng/ml, with moderate predictive values. The ACF score is a simple reliable system that can predict T2D remission among Chinese patients.</description><subject>Age</subject><subject>Analysis</subject><subject>Antidiabetics</subject><subject>Body mass index</subject><subject>Care and treatment</subject><subject>Diabetes</subject><subject>Diabetes therapy</subject><subject>Drugs</subject><subject>Endocrinology</subject><subject>Gastrointestinal surgery</subject><subject>Glycosylated hemoglobin</subject><subject>Homeostasis</subject><subject>Hypertension</subject><subject>Hypoglycemic agents</subject><subject>Insulin resistance</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Metabolism</subject><subject>Obesity</subject><subject>Peptides</subject><subject>Regression analysis</subject><subject>Remission (Medicine)</subject><subject>Type 2 diabetes</subject><issn>1687-8337</issn><issn>1687-8345</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNkstvEzEQxlcIREvhxhlZQkJIkNZvey9IVXhVakUF5cDJ8tqziaPtOrV3i_Lf45CQNogD8sGv33xjz3xV9ZzgY0KEOKGY4hNaS0GUeFAdEqnVRDMuHu7WTB1UT3JeYCylxORxdcAY11phcVj9uEzggxvCLaCL6KFDsUVXqyUgit4H28AAGX2F65BziD2y7QAJXcBgm9gFh76NaQZphUKPpvPQQwZ0aYcA_ZCfVo9a22V4tp2Pqu8fP1xNP0_Ov3w6m56eT5xkYpg0Tc2FqBvS6MZxTxkQr7wnqqFUWKxkC7Uva6vqVukySUGlZnXDKLdCADuqzja6PtqFWaZwbdPKRBvM74OYZsamIbgOjBVcNtrV0jnOAbClDa-Zh9aud6CK1ruN1nJsrsG78o9kuz3R_Zs-zM0s3hqltNKCF4HXW4EUb0bIgymVc9B1toc4ZkO5xkpQzNa5Xv6FLuKY-lKqQgnNiyQVd9TMlg-Evo0lr1uLmlNZK0yEpuu0x_-gyvClcy720IZyvhfw6l7AHGw3zHPsxqE0Oe-DbzegSzHnBO2uGASbtf_M2n9m67-Cv7hfwB38x3AFeLMBilu8_Rn-Uw4KU9p0R5PywJqyXx8y6aA</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Zhao, Shaoli</creator><creator>Yang, Youbo</creator><creator>He, Honghui</creator><creator>Guo, Zi</creator><creator>Luo, Yufang</creator><creator>Mo, Zhaohui</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2295-0213</orcidid><orcidid>https://orcid.org/0000-0002-5181-048X</orcidid></search><sort><creationdate>2020</creationdate><title>Predictive Model of Type 2 Diabetes Remission after Metabolic Surgery in Chinese Patients</title><author>Zhao, Shaoli ; Yang, Youbo ; He, Honghui ; Guo, Zi ; Luo, Yufang ; Mo, Zhaohui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c635t-bb94559b1b8bc4d23e1d7dd17b225a076fe9db22a79f782a76526839b324a55e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Age</topic><topic>Analysis</topic><topic>Antidiabetics</topic><topic>Body mass index</topic><topic>Care and treatment</topic><topic>Diabetes</topic><topic>Diabetes therapy</topic><topic>Drugs</topic><topic>Endocrinology</topic><topic>Gastrointestinal surgery</topic><topic>Glycosylated hemoglobin</topic><topic>Homeostasis</topic><topic>Hypertension</topic><topic>Hypoglycemic agents</topic><topic>Insulin resistance</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Metabolism</topic><topic>Obesity</topic><topic>Peptides</topic><topic>Regression analysis</topic><topic>Remission (Medicine)</topic><topic>Type 2 diabetes</topic><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Shaoli</creatorcontrib><creatorcontrib>Yang, Youbo</creatorcontrib><creatorcontrib>He, Honghui</creatorcontrib><creatorcontrib>Guo, Zi</creatorcontrib><creatorcontrib>Luo, Yufang</creatorcontrib><creatorcontrib>Mo, Zhaohui</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Shaoli</au><au>Yang, Youbo</au><au>He, Honghui</au><au>Guo, Zi</au><au>Luo, Yufang</au><au>Mo, Zhaohui</au><au>Kin, Tatsuya</au><au>Tatsuya Kin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive Model of Type 2 Diabetes Remission after Metabolic Surgery in Chinese Patients</atitle><jtitle>International journal of endocrinology</jtitle><addtitle>Int J Endocrinol</addtitle><date>2020</date><risdate>2020</risdate><volume>2020</volume><issue>2020</issue><spage>1</spage><epage>13</epage><pages>1-13</pages><issn>1687-8337</issn><eissn>1687-8345</eissn><abstract>Introduction. Metabolic surgery is an effective treatment for type 2 diabetes (T2D). At present, there is no authoritative standard for predicting postoperative T2D remission in clinical use. In general, East Asian patients with T2D have a lower body mass index and worse islet function than westerners. We aimed to look for clinical predictors of T2D remission after metabolic surgery in Chinese patients, which may provide insights for patient selection. Methods. Patients with T2D who underwent metabolic surgery at the Third Xiangya Hospital between October 2008 and March 2017 were enrolled. T2D remission was defined as an HbA1c level below 6.5% and an FPG concentration below 7.1 mmol/L for at least one year in the absence of antidiabetic medications. Results. (1) Independent predictors of short-term T2D remission (1-2 years) were age and C-peptide area under the curve (C-peptide AUC); independent predictors of long-term T2D remission (4–6 years) were C-peptide AUC and fasting plasma glucose (FPG). (2) The optimal cutoff value for C-peptide AUC in predicting T2D remission was 30.93 ng/ml, with a specificity of 67.3% and sensitivity of 75.8% in the short term and with a specificity of 61.9% and sensitivity of 81.5% in the long term, respectively. The areas under the ROC curves are 0.674 and 0.623 in the short term and long term, respectively. (3) We used three variables (age, C-peptide AUC, and FPG) to construct a remission prediction score (ACF), a multidimensional 9-point scale, along which greater scores indicate a better chance of T2D remission. We compared our scoring system with other reported models (ABCD, DiaRem, and IMS). The ACF scoring system had the best distribution of patients and prognostic significance according to the ROC curves. Conclusion. Presurgery age, C-peptide AUC, and FPG are independent predictors of T2D remission after metabolic surgery. Among these, C-peptide AUC plays a decisive role in both short- and long-term remission prediction, and the optimal cutoff value for C-peptide AUC in predicting T2D remission was 30.93 ng/ml, with moderate predictive values. The ACF score is a simple reliable system that can predict T2D remission among Chinese patients.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>33488705</pmid><doi>10.1155/2020/2965175</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-2295-0213</orcidid><orcidid>https://orcid.org/0000-0002-5181-048X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1687-8337 |
ispartof | International journal of endocrinology, 2020, Vol.2020 (2020), p.1-13 |
issn | 1687-8337 1687-8345 |
language | eng |
recordid | cdi_pubmed_primary_33488705 |
source | Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
subjects | Age Analysis Antidiabetics Body mass index Care and treatment Diabetes Diabetes therapy Drugs Endocrinology Gastrointestinal surgery Glycosylated hemoglobin Homeostasis Hypertension Hypoglycemic agents Insulin resistance Medical research Medicine, Experimental Metabolism Obesity Peptides Regression analysis Remission (Medicine) Type 2 diabetes |
title | Predictive Model of Type 2 Diabetes Remission after Metabolic Surgery in Chinese Patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T16%3A58%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20Model%20of%20Type%202%20Diabetes%20Remission%20after%20Metabolic%20Surgery%20in%20Chinese%20Patients&rft.jtitle=International%20journal%20of%20endocrinology&rft.au=Zhao,%20Shaoli&rft.date=2020&rft.volume=2020&rft.issue=2020&rft.spage=1&rft.epage=13&rft.pages=1-13&rft.issn=1687-8337&rft.eissn=1687-8345&rft_id=info:doi/10.1155/2020/2965175&rft_dat=%3Cgale_doaj_%3EA697015824%3C/gale_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2458477825&rft_id=info:pmid/33488705&rft_galeid=A697015824&rft_doaj_id=oai_doaj_org_article_a546b8c96cc44ee0a2b493defa4ee0e7&rfr_iscdi=true |